Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BeyondSpring Inc.
  6. Company
    BYSI   KYG108301006

BEYONDSPRING INC.

(BYSI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Business Summary
BeyondSpring Inc. is a clinical-stage global biopharmaceutical company. The Company is focused on developing cancer therapies to improve clinical outcomes for patients who have high unmet medical needs. The Company’s lead product Plinabulin, which is being studied as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). The Plinabulin is a small molecule derived from a natural compound found in marine microorganisms. Its Plinabulin is a selective immunomodulating microtubule-binding agent (SIMBA) with a range of immune activities. Its Plinabulin activates immune defense protein GEF-H1, which leads to two effects: a durable anti-cancer benefits due to the maturation of dendritic cells resulting in activation of tumor antigen-specific T-cells to target cancer cells and early-onset action in chemotherapy-induced neutropenia (CIN) prevention after chemotherapy by boosting the number of hematopoietic stem/progenitor cells (HSPCs).

Number of employees : 76 people.
Sales per Business
20202021Delta
Cancer Therapies0.18100%1.35100% +650.56%
USD in Million
Sales per region
20202021Delta
United States0.18100%1.35100% +650.56%
USD in Million
Managers
Name Title Age Since
Lan Huang, Dr. Chairman & Chief Executive Officer 50 2014
Elizabeth Adkins Czerepak Chief Financial Officer 65 2020
Ramon Mohanlal Director, Chief Medical Officer, Executive VP-R&D 62 2020
G. Kenneth Lloyd, Dr. Chief Scientific Officer 77 2021
Gordon Leroy Schooley, Dr. Chief Regulatory Officer 74 2016
Members of the board
Name Title Age Since
Lan Huang, Dr. Chairman & Chief Executive Officer 50 2014
Matthew Kirkby Independent Director 52 2016
Patrick Fabbio Independent Director 54 2018
Daniel L. Zabrowski, Dr. Independent Director 63 2020
Jeffrey L. Vacirca, Dr. Independent Director 52 2020
Brendan Delaney Independent Director 46 2021
Ramon Mohanlal Director, Chief Medical Officer, Executive VP-R&D 62 2020
Yanbin Xie, Dr. Director 63 2016
Christine Ying Zhao Independent Director 48 2016
Mark Santos Director - 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 38,927,563 18,522,406 47.6% 0 0.0% 47.6%
Shareholders
NameEquities%
Lan Huang 10,370,523 26.6%
Decheng Capital LLC 4,958,142 12.7%
Mulong Liu 1,254,622 3.22%
Millennium Management LLC 691,826 1.78%
Quan Qi Song 691,119 1.78%
Sphera Funds Management Ltd. 598,000 1.54%
Morgan Stanley & Co. LLC 380,326 0.98%
Renaissance Technologies LLC 366,959 0.94%
D. E. Shaw & Co. LP 350,143 0.90%
BNP Paribas Arbitrage SNC 249,308 0.64%
Company contact information
BeyondSpring, Inc.
28 Liberty Street
39th floor
New York, NY 10005

Phone : +1.646.305.6387
Fax : +1.646.882.4228
Web : http://www.beyondspringpharma.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of BeyondSpring Inc.